/SION
SION Stock - Sionna Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$42.37-4.16%
$1.84 (-4.16%) • Dec 19
35
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.SELL
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).0
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+-43.4%upside
Target: $23.98
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for SION
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$41.95 – $42.79
TARGET (TP)$24.00
STOP LOSS$38.98
RISK/REWARD1:-5.4
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta3.46
52W High$45.00
52W Low$7.25
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | N/A | N/A | N/A |
| Gross Profit | $-668,000 | N/A | N/A |
| Gross Margin | N/A | N/A | N/A |
| Operating Income | $-70,556,000 | $-50,333,000 | $-41,372,000 |
| Net Income | $-61,688,000 | $-47,263,000 | $-40,240,000 |
| Net Margin | N/A | N/A | N/A |
| EPS | $-1.40 | $-1.07 | $-0.91 |
Company Overview
Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
Visit WebsiteRating Distribution
Strong Buy
1
17%
Buy / Outperform
4
67%
Hold / Neutral
0%
Sell / Underperform
1
17%
Analyst Consensus🟢 Bullish
5 Bullish1 Neutral/Bearish
Price Targets
$36
Average Target
↓ 14.2% Downside
Now
$22
Low
$36
Average
$50
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 1st 2025 | RBC Capital Mkts | Downgrade | Underperform | $24 |
| November 19th 2025 | BTIG Research | Initiation | Buy | $50 |
| September 3rd 2025 | Raymond James | Initiation | Strong Buy | $45 |
| September 3rd 2025 | RBC Capital Mkts | Initiation | Sector Perform | $22 |
| March 4th 2025 | TD Cowen | Initiation | Buy | - |
| March 4th 2025 | Stifel | Initiation | Buy | $32 |
| March 4th 2025 | Guggenheim | Initiation | Buy | $45 |
Earnings History & Surprises
SIONBeat Rate
50%
Last 4 quarters
Avg Surprise
-119.9%
EPS vs Estimate
Beats / Misses
2/2
Last 12 quarters
Latest EPS
$-0.46
Q4 2025
EPS Surprise History
Q4 24
No data
Q1 25
-493.0%
$-3.38vs$-0.57
Q2 25
-37.8%
$-0.62vs$-0.45
Q3 25
+39.7%
$-0.41vs$-0.68
Q4 25
+11.5%
$-0.46vs$-0.52
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 19, 2026 | $-0.61 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-0.52 | $-0.46 | +11.5% | ✓ BEAT |
Q3 2025 | Aug 11, 2025 | $-0.68 | $-0.41 | +39.7% | ✓ BEAT |
Q2 2025 | May 12, 2025 | $-0.45 | $-0.62 | -37.8% | ✗ MISS |
Q1 2025 | Mar 20, 2025 | $-0.57 | $-3.38 | -493.0% | ✗ MISS |
Q4 2024 | Nov 27, 2024 | — | $-0.92 | — | — |
Latest News
Sionna Therapeutics shares are trading lower after RBC Capital downgraded the stock from Sector Perform to Underperform.
📉 NegativeBenzinga•Dec 1, 2025, 04:21 PM
RBC Capital Downgrades Sionna Therapeutics to Underperform, Maintains Price Target to $24
📉 NegativeBenzinga•Dec 1, 2025, 02:27 PM
BTIG Initiates Coverage On Sionna Therapeutics with Buy Rating, Announces Price Target of $50
📈 PositiveBenzinga•Nov 19, 2025, 10:14 AM•Also:
Sionna Therapeutics Q3 EPS $(0.46) Beats $(0.49) Estimate
📈 PositiveBenzinga•Nov 5, 2025, 12:11 PM
Sionna Therapeutics Presents SION-719 And SION-451 Phase 1 Data, And New Preclinical Data Showing NBD1 Stabilizer Impact On F508del-CFTR Half-Life, At NACFC 2025
📈 PositiveBenzinga•Oct 24, 2025, 05:21 PM
Sionna Therapeutics shares are trading higher. The company initiated its PreciSION CF phase 2a proof-of-concept trial of SION-719.
📈 PositiveBenzinga•Oct 21, 2025, 05:24 PM
Sionna Therapeutics Initiates PreciSION CF Phase 2a POC Trial Evaluating SION-719, NBD1 Stabilizer, When Added To Trikafta, Current Standard Of Care In CF; Topline Data Expected In Mid-2026
📈 PositiveBenzinga•Oct 21, 2025, 11:12 AM
Sionna Therapeutics Initiates PreciSION CF Phase 2a Proof-Of-Concept Trial Of SION-719
📈 PositiveBenzinga•Oct 21, 2025, 11:04 AM
Freedom Capital Markets Initiates Coverage On Sionna Therapeutics with Buy Rating, Announces Price Target of $38
📈 PositiveBenzinga•Oct 17, 2025, 07:02 PM
Jones Trading Initiates Coverage On Sionna Therapeutics with Buy Rating, Announces Price Target of $46
📈 PositiveBenzinga•Sep 8, 2025, 04:24 PM
Raymond James Initiates Coverage On Sionna Therapeutics with Strong Buy Rating, Announces Price Target of $45
📈 PositiveBenzinga•Sep 3, 2025, 04:56 PM
RBC Capital Initiates Coverage On Sionna Therapeutics with Sector Perform Rating, Announces Price Target of $22
➖ NeutralBenzinga•Sep 3, 2025, 01:53 PM
Sionna Therapeutics Doses First Subjects In Phase 1 Trial Of NBD1 Stabilizer SION-451 In Proprietary Dual Combinations
📈 PositiveBenzinga•Aug 25, 2025, 11:05 AM
Frequently Asked Questions about SION
What is SION's current stock price?
Sionna Therapeutics, Inc. (SION) is currently trading at $42.37 per share. The stock has moved -4.16% today.
What is the analyst price target for SION?
The average analyst price target for SION is $24.00, based on 1 analyst.
What sector is Sionna Therapeutics, Inc. in?
Sionna Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is SION's market cap?
Sionna Therapeutics, Inc. has a market capitalization of $1.89 billion, making it a small-cap company.
Does SION pay dividends?
No, Sionna Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABCL
AbCellera Biologics Inc.
$3.60
Mkt Cap: $1.1B
ARDX
Ardelyx, Inc.
$5.68
Mkt Cap: $1.4B
BHVN
Biohaven Ltd.
$10.85
Mkt Cap: $1.1B
CLDX
Celldex Therapeutics, Inc.
$25.60
Mkt Cap: $1.7B
IMNM
Immunome, Inc.
$21.44
Mkt Cap: $2.0B
JANX
Janux Therapeutics, Inc.
$13.79
Mkt Cap: $0.8B
MAZE
Maze Therapeutics, Inc.
$41.71
Mkt Cap: $2.0B
VERA
Vera Therapeutics, Inc.
$51.22
Mkt Cap: $3.3B
XERS
Xeris Biopharma Holdings, Inc.
$7.34
Mkt Cap: $1.2B
ZYME
Zymeworks Inc.
$27.23
Mkt Cap: $2.0B
Explore stocks similar to SION for comparison